Corsalex, Inc.
Piero Mendez is a seasoned professional in the biotechnology and healthcare sectors, currently serving as Managing Director at Panorama Research Inc. since July 2020, where notable achievements include the acquisitions of MilkyWay Biopharma by Corbus Pharmaceuticals and Nepenthe Biosciences by Pfizer, Inc. As Co-Founder and Managing Partner at Corsalex, Inc. since January 2022, Piero focuses on developing therapies for C9orf72 ALS/FTD. Piero has also been a Board Member at Pyrogenyx, Inc. since May 2021 and previously co-founded Empire Biotechnologies, where efforts were directed toward therapies for gastrointestinal diseases. Furthermore, Piero held leadership roles at Life Science Angels, overseeing clinical and technical due diligence for investment opportunities from January 2016 to August 2018. Piero's entrepreneurial experience includes co-owning Wydown Water LLC from May 2010 to June 2013, and academic credentials include a Bachelor of Science in Biomedical/Medical Engineering from Washington University in St. Louis.
This person is not in any teams
Corsalex, Inc.
Corsalex’s mission is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative diseases. Genetic analysis has revealed the hexanucleotide repeat expansion (HRE) disorder C9orf72 as the most common cause of familial ALS/FTD (C9-ALS/FTD). Corsalex is a joint venture between KCK and Panorama Research. Led by Dr. James Larrick, a biomedical entrepreneur with an international reputation and over 30-year career in biotechnology, and backed by KCK, the Company hopes to spur innovation and advance meaningful interventions for this devastating disease.